0

530057

VIVANZA

img img img img
No Data Available

Vivanza Biosciences Limited Share Price Update

As of the latest trading session, Vivanza Biosciences Limited is trading at ₹1.9, down by ₹-0.09 or -4.52% from its previous close. The stock has moved between ₹1.90 and ₹1.99 today. Over the past year, the stock has delivered a return of -11.21%. In the last month, it has returned -5.00%.

Investment Returns

Over 1 Month -5.00% Over 3 Months -7.31% Over 6 Months -3.55% Over 1 Year -11.21%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Vivanza Biosciences Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 7.60
  • P/E Ratio (TTM) 22.11
  • Beta 0.27
  • Book Value / share 1.10
  • Return on equity -16.02%
  • EPS (TTM) 0.09
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -0.27
info icon alternate text

Vivanza Biosciences Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 5.75
Operating Expense 5.88
Net Profit -0.27
Net Profit Margin (%) -4.69
Earnings Per Share (EPS) -0.07
EBITDA -0.03
Effective Tax Rate (%) -116.66
Particulars DEC 2025 (Values in Cr)
Revenue 44.93
Operating Expense 44.85
Net Profit 0.16
Net Profit Margin (%) 0.35
Earnings Per Share (EPS) 0.04
EBITDA 0.25
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 53.73
Operating Expense 53.27
Net Profit 0.46
Net Profit Margin (%) 0.85
Earnings Per Share (EPS) 0.12
EBITDA 0.51
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 7.82
Operating Expense 7.82
Net Profit 0.02
Net Profit Margin (%) 0.25
Earnings Per Share (EPS) 0.00
EBITDA 0.10
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 0.17
Operating Expense 1.15
Net Profit -0.97
Net Profit Margin (%) -570.58
Earnings Per Share (EPS) -0.24
EBITDA -0.88
Effective Tax Rate (%) 0.00
Particulars MAR 2026 (Values in Cr)
Revenue 112.23
Operating Expense 111.82
Net Profit 0.38
Net Profit Margin (%) 0.33
Earnings Per Share (EPS) 0.09
EBITDA 0.82
Effective Tax Rate (%) 26.92
Particulars MAR 2025 (Values in Cr)
Revenue 2.94
Operating Expense 3.67
Net Profit -0.70
Net Profit Margin (%) -23.80
Earnings Per Share (EPS) -0.17
EBITDA -0.32
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 14.41
Operating Expense 14.04
Net Profit 0.32
Net Profit Margin (%) 2.22
Earnings Per Share (EPS) 0.08
EBITDA 0.85
Effective Tax Rate (%) 25.58
Particulars MAR 2023 (Values in Cr)
Revenue 14.21
Operating Expense 13.91
Net Profit 0.57
Net Profit Margin (%) 4.01
Earnings Per Share (EPS) 1.42
EBITDA 1.10
Effective Tax Rate (%) 17.39
Particulars MAR 2022 (Values in Cr)
Revenue 9.15
Operating Expense 9.52
Net Profit 0.46
Net Profit Margin (%) 5.02
Earnings Per Share (EPS) 1.16
EBITDA 0.88
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share 0.99
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 1.61
EBITDA Margin -4.04
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.16
ROE % 12.60
ROCE % 10.23
Total Debt to Total Equity 1.51
EBITDA Margin 4.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.02
ROE % 14.84
ROCE % 10.65
Total Debt to Total Equity 1.78
EBITDA Margin 6.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.73
ROE % 8.25
ROCE % 10.96
Total Debt to Total Equity 0.88
EBITDA Margin 7.40
Particulars MAR 2021 (Values in Cr)
Book Value / Share 7.90
ROE % 2.26
ROCE % 15.32
Total Debt to Total Equity 0.12
EBITDA Margin 6.07
Particulars MAR 2025 (Values in Cr)
Book Value / Share 1.01
ROE % -16.02
ROCE % -3.87
Total Debt to Total Equity 1.07
EBITDA Margin -11.22
Particulars MAR 2024 (Values in Cr)
Book Value / Share 1.18
ROE % 7.02
ROCE % 8.98
Total Debt to Total Equity 1.08
EBITDA Margin 5.97
Particulars MAR 2023 (Values in Cr)
Book Value / Share 1.10
ROE % 13.57
ROCE % 11.56
Total Debt to Total Equity 1.33
EBITDA Margin 7.88
Particulars MAR 2022 (Values in Cr)
Book Value / Share 9.57
ROE % 11.50
ROCE % 14.13
Total Debt to Total Equity 0.64
EBITDA Margin 9.84
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.41
ROE % 2.75
ROCE % 16.25
Total Debt to Total Equity 0.05
EBITDA Margin 6.83
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 16.45
Total Liabilities 16.45
Total Equity 3.96
Share Outstanding 4
Price to Book Ratio 1.97
Return on Assets (%) -4.09
Return on Capital (%) -5.34
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.16
Total Assets 19.50
Total Liabilities 19.50
Total Equity 4.63
Share Outstanding 4
Price to Book Ratio 5.75
Return on Assets (%) 2.80
Return on Capital (%) 5.58
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.14
Total Assets 22.47
Total Liabilities 22.47
Total Equity 4.09
Share Outstanding 4
Price to Book Ratio 17.09
Return on Assets (%) 2.66
Return on Capital (%) 4.95
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.05
Total Assets 15.56
Total Liabilities 15.56
Total Equity 3.49
Share Outstanding 0
Price to Book Ratio 19.71
Return on Assets (%) 2.13
Return on Capital (%) 3.7
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments -3.09
Total Assets 8.44
Total Liabilities 8.44
Total Equity 3.15
Share Outstanding 0
Price to Book Ratio 15.53
Return on Assets (%) 0.89
Return on Capital (%) 2.14
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.04
Total Assets 13.91
Total Liabilities 13.91
Total Equity 4.02
Share Outstanding 4
Price to Book Ratio 1.97
Return on Assets (%) -4.99
Return on Capital (%) -6.87
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.09
Total Assets 16.87
Total Liabilities 16.87
Total Equity 4.71
Share Outstanding 4
Price to Book Ratio 5.75
Return on Assets (%) 1.88
Return on Capital (%) 3.98
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 20.44
Total Liabilities 20.44
Total Equity 4.39
Share Outstanding 4
Price to Book Ratio 17.09
Return on Assets (%) 2.78
Return on Capital (%) 5.19
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.01
Total Assets 14.20
Total Liabilities 14.20
Total Equity 3.82
Share Outstanding 0
Price to Book Ratio 19.71
Return on Assets (%) 3.26
Return on Capital (%) 5.62
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments -3.11
Total Assets 7.93
Total Liabilities 7.93
Total Equity 3.36
Share Outstanding 0
Price to Book Ratio 15.53
Return on Assets (%) 1.25
Return on Capital (%) 2.82
Particulars MAR 2025 (Values in Cr)
Net Income -0.66
Cash from Operations -2.49
Cash from Investing 0.00
Cash from Financing 2.45
Net change in Cash -0.05
Free Cash Flow -2.48
Particulars MAR 2024 (Values in Cr)
Net Income 0.69
Cash from Operations 2.19
Cash from Investing -0.03
Cash from Financing -1.98
Net change in Cash 0.02
Free Cash Flow 2.23
Particulars MAR 2023 (Values in Cr)
Net Income 0.71
Cash from Operations -0.82
Cash from Investing 0.00
Cash from Financing 1.03
Net change in Cash 0.08
Free Cash Flow -0.82
Particulars MAR 2022 (Values in Cr)
Net Income 0.33
Cash from Operations 2.46
Cash from Investing 0.00
Cash from Financing -2.47
Net change in Cash -0.01
Free Cash Flow 2.46
Particulars MAR 2021 (Values in Cr)
Net Income 0.14
Cash from Operations -3.02
Cash from Investing -0.02
Cash from Financing 2.79
Net change in Cash -0.30
Free Cash Flow -3.00
Particulars MAR 2025 (Values in Cr)
Net Income -0.69
Cash from Operations -2.46
Cash from Investing 0.00
Cash from Financing 2.43
Net change in Cash -0.04
Free Cash Flow -2.46
Particulars MAR 2024 (Values in Cr)
Net Income 0.42
Cash from Operations 1.90
Cash from Investing -0.03
Cash from Financing -1.77
Net change in Cash -0.01
Free Cash Flow 1.94
Particulars MAR 2023 (Values in Cr)
Net Income 0.68
Cash from Operations 0.27
Cash from Investing 0.00
Cash from Financing -0.07
Net change in Cash 0.08
Free Cash Flow 0.27
Particulars MAR 2022 (Values in Cr)
Net Income 0.46
Cash from Operations -0.67
Cash from Investing 0.00
Cash from Financing 0.65
Net change in Cash -0.02
Free Cash Flow -0.67
Particulars MAR 2021 (Values in Cr)
Net Income 0.14
Cash from Operations -3.02
Cash from Investing -0.02
Cash from Financing 2.79
Net change in Cash -0.30
Free Cash Flow -3.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.09 14.32 1.71 253.58 23.12 40.44
BLISS GVS PHARMA LTD. 269.35 25.75 2.51 2849.43 105.05 280.20
CIPLA LTD 1347.70 22.90 3.30 108864.87 1165.55 1672.20
FERMENTA BIOTECH LTD. 288.70 9.60 2.17 849.67 252.15 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENTERPRISES L 33.09 31.82 4.61 253.58 23.12 40.44
AMRUTANJAN HEALTH CARE LTD. 548.80 27.44 4.63 1586.62 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8489.25 102.02 26.56 21223.13 7630.00 10653.05
BLISS GVS PHARMA LTD. 269.35 36.70 2.58 2849.43 105.05 280.20

Vivanza Biosciences Limited shareholding pattern

Holding
79.97%
20.01%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Vivanza Biosciences Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1.90 -4.52 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 2.00
  • 26 Days 2.00
  • 10 Days 2.00
  • 50 Days 2.00
  • 12 Days 2.00
  • 100 Days 2.00
  • 20 Days 2.00
  • 200 Days 2.20
2.00 PIVOT
First Support 2.00 First Resistance 2.01 Second Support 1.99 Second Resistance 2.01 Third Support 1.99 Third Resistance 2.02
RSI 42.44 ADX 8.50 MACD 0.00 Williams % R -83.33 Commodity Channel Index (CCI) -179.34
Date 2026-05-08 Week 24275.00 Same Day 82347.00 Month 16509.00
1 Year 0.34 3 Year 0.31
Over 1 Month
-5.00% down
Over 1 Year
-11.21% down
Over 3 Months
-7.31% down
Over 3 Years
-50.14% down
Over 6 Months
-3.55% down
Over 5 Years
-21.71% down

Vivanza Biosciences Limited Corporate Actions

Ex-Date Old FV NEW FV Record Date
24 Mar 2023 10.0 1.0 24 Mar 2023

Top Gainers

Top Losers

Vivanza Biosciences Limited Share Price

Vivanza Biosciences Limited, formerly known as Ivee Injectaa Limited was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992. Due to recessionary trends which lead to difficult business conditions in year 1999-2000, the parenteral industry suffered a setback and due to this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015.

The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. It is presently engaged in the business of Pharmaceutical Products.

Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system. Company undertook an expansion-cum-diversification programme to increase its capacity from 18 lac pa to 54 lac pa. It came out with a public issue of 21,70,000 equity shares of Rs 10 each for cash at par aggregating Rs 217 lac. It is one of the few companies which has facilities for both glass as well as plastic containers.

The Company acquired 100% Equity Shares of Vivanza Lifesciences Private Limited, making it a Wholly Owned Subsidiary w.e.f. 17 June, 2016.

Parent organization Indian Private
NSE symbol [-]
Founded 1982
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Vivanza Biosciences Ltd?

Answer Field

Vivanza Biosciences Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 1.90 as on May 12 2026 03:15 PM.

What is the Market Cap of Vivanza Biosciences Ltd Share?

Answer Field

The market cap of Vivanza Biosciences Ltd for NSE ₹ 0.00 & for BSE ₹ 7.60 as on May 12 2026 03:15 PM.

What is the 52 Week High and Low of Vivanza Biosciences Ltd?

Answer Field

The 52 Week High and Low of Vivanza Biosciences Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 2.94 and ₹ 1.75.

What is 1 year return for Vivanza Biosciences Ltd?

Answer Field

The 1 year returns on the stock has been -6.13%.

What is the P/E Ratio of Vivanza Biosciences Ltd Share?

Answer Field

As on May 12 2026 03:15 PM the price-to-earnings (PE) ratio for Vivanza Biosciences Ltd share is 22.11.

What is the PB ratio of Vivanza Biosciences Ltd Share?

Answer Field

As on May 12 2026 03:15 PM, the price-to-book (PB) ratio for Vivanza Biosciences Ltd share is 1.10.

How to Buy Vivanza Biosciences Ltd Share?

Answer Field

You can trade in Vivanza Biosciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vivanza Biosciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Vivanza Biosciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vivanza Biosciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|